00:00 / 00:00
SULFONYLUREAS & MEGLITINIDES | ||
DRUG NAME | First generation: tolbutamide, tolazamide, chlorpropamide Second generation: glimepiride (Amaryl), glipizide (Glucotrol), glyburide (Glynase) *High Alert Medications* | repaglinide, nateglinide *High Alert Medications* |
CLASS | Sulfonylureas | Meglitinides |
MECHANISM OF ACTION | Inhibit ATP-sensitive K+ channels on pancreatic beta cells → increase insulin secretion → decrease blood glucose levels | |
INDICATIONS | Type 2 diabetes mellitus | |
ROUTE(S) OF ADMINISTRATION | PO | |
SIDE EFFECTS |
| |
CONTRAINDICATIONS AND CAUTIONS |
|
NURSING CONSIDERATIONS: SULFONYLUREAS & MEGLITINIDES | ||
ASSESSMENT AND MONITORING | Sulfonylureas and meglitinides Assess
Monitor
| |
CLIENT EDUCATION | Sulfonylureas and meglitinides
|
Sulfonylureas and meglitinides are medications used to treat type 2 diabetes mellitus. Type 2 diabetes is characterized by insulin resistance, which is when tissue cells have trouble responding to insulin in order to use glucose from the blood.
As a result, tissue cells starve for energy despite having high blood glucose levels, which is called hyperglycemia.
Now, sulfonylureas can be classified into first and second generation, and are easy to recognize because they all have the suffix -ide.
First generation sulfonylureas include tolbutamide, which is short-acting, tolazamide, which is intermediate-acting, and chlorpropamide, which is long-acting; while second generation sulfonylureas include glimepiride, glipizide and glyburide
On the other hand, meglitinides have the suffix -glinide, and the most commonly used ones include repaglinide and nateglinide.
Okay, now both sulfonylureas and meglitinides are given orally and once administered, they both act on the pancreas by inhibiting ATP-sensitive potassium channels on the membrane of pancreatic beta cells.
As a result, these medications initiate a cascade of events that stimulate the pancreatic beta cells to secrete more insulin, ultimately leading to a decrease in blood glucose levels.
Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.